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Branching out 
requires VEGF
 
ot all isoforms are created equal. New 
results from Christiana Ruhrberg, 
David Shima (Cancer Research UK, 
London, UK), and colleagues reveal that 
the stickiness of vascular endothelial growth 
factor (VEGF) can make all the difference 
between blood vessels growing larger or 
finding new territory.
VEGF initiates the formation and expansion 
of the vascular system. VEGF isoforms differ 
in their ability to bind to the extracellular 
matrix (ECM), but, in vitro, endothelial 
cell proliferation is stimulated by VEGF 
regardless of its ECM-binding ability.
In the new study, Shima’s group examined 
mice engineered to make only single VEGF 
isoforms. These mice reveal that VEGF 
isoforms have opposing effects on growing 
vessel networks. Although all forms stimulated 
cell growth in vivo, mice that expressed only 
soluble VEGF had expanded microvessels 
with fewer branches. In contrast, microvessels 
in mice with only ECM-binding VEGF were 
narrow and branched excessively.
“Our results indicate that growth is 
integrated with tissues, because the tissue 
provides localized cues by depositing VEGF 
in precise spatial patterns,” says Ruhrberg. 
The road map is provided by ECM-bound 
VEGF, which attracted filopodia extending 
from the tip of a new vessel branch. Soluble 
VEGF did not remain where it was secreted, 
but rather traveled further away, thus 
stimulating expansion of existing vessels 
from a distance. The authors hope to raise 
awareness of isoform-specific effects for 
those considering the use of VEGF for 
therapy to increase or block angiogenesis.
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Blood vessels are missing branches in 
mice with no ECM-bound VEGF (right). 
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An amidation a day keeps apoptosis away
 
apidly dividing cells such as tumor cells are susceptible to DNA damage that 
then induces apoptosis. As a result, DNA-damaging chemicals such as cisplatin 
are used as anticancer treatments. How the majority of nontumor cells survive 
chemotherapy has been mysterious. The trivial explanation is that the cells are 
growth-arrested and thus less susceptible to DNA-damaging agents. But a more 
precise explanation is put forth in a new article by Benjamin Deverman, Steven 
Weintraub (Washington University, St. Louis, MO), and colleagues, who have identified 
an antiapoptotic activity necessary to keep damaged but nondividing cells alive.
The proapoptotic activity that allows tumor 
cells to die is an unusual modification of the 
antiapoptotic protein Bcl-x
 
L
 
 caused by DNA-
damaging agents. This modification, deamidation 
of two asparagine residues, inactivated Bcl-x
 
L
 
, 
thereby allowing cell death to proceed. Growth-
arrested cells escaped apoptosis by blocking 
deamidation. To prevent deamidation, cells 
needed Rb, a tumor suppressor protein that inhibits cell cycle progression. Because 
tumor cells lack Rb, and cycling cells down-regulate Rb, they are more sensitive to 
DNA-damaging agents. “Deamidation is like a checkpoint,” says Weintraub. “If you 
undergo DNA damage in the absence of Rb, then cells are susceptible to death.”
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R
Bcl-xL modification by cisplatin 
is blocked by Rb.
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Arrested cells are Mad as Hec
 
he spindle checkpoint works even when on the move, according to new 
results from Silvia Martin-Lluesma, Volker Stucke, and Erich Nigg (Max-
Planck Institute of Biochemistry, Martinsried, Germany). Against all that has 
been sacred in the field, these researchers find that mitosis can be arrested 
when checkpoint proteins leave the kinetochore.
The checkpoint is activated by 
Mad1 and Mad2 proteins, which 
bind to kinetochores that are not 
attached to the spindle micro-
tubules. The prevailing theory 
has been that release of Mad1/
Mad2 inactivates the checkpoint 
and allows mitosis to proceed.
Nigg and colleagues looked for human Mad1-interacting proteins and 
found Hec1, which recruited Mad1 and Mad2 to kinetochores. Given this 
function, the group was surprised to find that reducing Hec1 prevented 
cells from dividing, despite the fact that Mad1/Mad2 were not on the 
kinetochores. “This is different from all that has been shown so far,” says 
Stucke. “The components are depleted [from kinetochores], but you still 
get arrest and an active checkpoint.” Hec1-depleted cells that also lacked 
Mad2 continued through mitosis and ended in mitotic catastrophe. Thus, 
checkpoint components can signal from the cytoplasm.
According to one model of Mad function, the Mad proteins make a brief 
visit to kinetochores to sample the environment, but then propagate their 
inhibitory signal in the cytoplasm. Hec1 may regulate this process, but for 
now the details of Hec1 action remain obscure. 
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Cells without Hec1 (right) stall in mitosis 
although Mad is not at kinetochores.
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